Poland· PL-100441818
Jyseleca
A filgotinib product containing filgotinibum, registered in Poland by Alfasigma S.p.A.. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Filgotinib is registered in 10 of 19 countries.
Countries holding a registration under ATC L04AF04 (filgotinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Filgotinib · ATC L04AF04
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Filgotinibum
- Manufacturer
- Alfasigma S.p.A.
- Country
- Poland (PL)
- ATC code
- L04AF04
- ATC class
- Filgotinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05391507146366
- gtin05391507146731
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Filgotinib in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJYSELECAAlfasigma S.p.A., Bologna
- SpainJYSELECA 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAlfasigma S.P.A.
- FinlandJyselecaALFASIGMA S.p.A.
- FranceJYSELECA 100 mg, comprimé pelliculéALFASIGMA (ITALIE)
- IrelandJyseleca 100 mg film-coated tabletsAlfasigma S.p.A
- IcelandJyselecaAlfaSigma S.p.A.
- NetherlandsJyseleca 100 mg, filmomhulde tablettenAlfasigma S.p.A.
- NorwayJyselecaAlfasigma S.p.A
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jyseleca
- Liechtenstein · Jyseleca
- Norway · Jyseleca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8a2024f5-99e6-462a-b9c7-eeca4a35eab8 GET /v1/drugs/8a2024f5-99e6-462a-b9c7-eeca4a35eab8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "100 mg",
"packaging": "05391507146366 ¦ Rpz ¦ EU/1/20/1480/001 ¦ 137775\n1 butelka 30 tabl.\n¦ UR/Z/4c/072/22 - 05391507146731\nRpz ¦ EU/1/20/1480/002 ¦ 137776\n3 butelki 30 tabl.",
"substance": "Filgotinibum 100 mg",
"common_name": "Filgotinibum",
"pl_product_id": "100441818",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about filgotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.